% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Trares:178311,
      author       = {K. Trares$^*$ and L.-J. Chen$^*$ and B. Schöttker$^*$},
      title        = {{A}ssociation of {F}2-isoprostane levels with {A}lzheimer's
                      disease in observational studies: a systematic review and
                      meta-analysis.},
      journal      = {Ageing research reviews},
      volume       = {74},
      issn         = {1568-1637},
      address      = {Oxford [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2021-03258},
      pages        = {101552},
      year         = {2021},
      note         = {#EA:C070#LA:C070#},
      abstract     = {The association between F2-isoprostanes and Alzheimer's
                      disease (AD) has been controversially discussed in the
                      literature since the 1990s. However, no systematic review
                      has been performed so far.A systematic review of
                      observational studies on the associations of F2-isoprostanes
                      and the specific biomarker 8-iso-prostaglandin F2α with AD
                      were conducted. Random-effects model meta-analyses were
                      performed.29 studies were included in the systematic review,
                      including four longitudinal studies. In an overall
                      meta-analysis of the 25 cross-sectional studies,
                      F2-isoprostane levels were statistically significantly
                      associated with AD (Hedge's g $[95\%$ confidence interval]:
                      1.00 [0.69-1.32]). When studies were grouped by biomarker
                      and sample specimen, F2-isoprostane and 8-iso-prostaglandin
                      F2α levels were statistically significantly elevated in
                      tissue samples of the frontal lobe of AD patients. Moreover,
                      F2-isoprostane levels in cerebrospinal fluid and
                      8-iso-prostaglandin F2α levels in blood samples of AD
                      patients were significantly increased. Meta-analyses of the
                      few longitudinal studies did not reach statistical
                      significance.Increased concentrations of F2-isoprostanes
                      were found in AD patients. However, due to the lack of
                      adjustment in most cross-sectional case-control studies,
                      results must be interpreted carefully. In addition, the
                      causality of the association is uncertain because evidence
                      from well-conducted longitudinal studies was conflicting,
                      and further longitudinal studies are required to reinforce
                      the results.},
      subtyp        = {Review Article},
      keywords     = {8-iso-prostaglandin F(2α) (Other) / Alzheimer’s Disease
                      (Other) / F(2)-isoprostanes (Other) / Observational studies
                      (Other) / Oxidative stress (Other) / Systematic review
                      (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34954419},
      doi          = {10.1016/j.arr.2021.101552},
      url          = {https://inrepo02.dkfz.de/record/178311},
}